Proniuk Stefan 4
4 · Arno Therapeutics, Inc · Filed May 30, 2013
Insider Transaction Report
Form 4
Proniuk Stefan
VP of Product Development
Transactions
- Other
Common Stock
2013-05-28$0.30/sh+1,289$387→ 3,955 total
Holdings
- 66,667
Series B Warrants (right to buy)
Exercise: $0.30From: 2012-11-26Exp: 2014-05-26→ Common Stock (66,667 underlying) - 57,534
Stock Option (right to buy)
Exercise: $0.30Exp: 2021-06-20→ Common Stock (57,534 underlying) - 55,000
Stock Option (right to buy)
Exercise: $0.30Exp: 2023-01-14→ Common Stock (55,000 underlying) - 18,333
Stock Option (right to buy)
Exercise: $0.30Exp: 2023-01-14→ Common Stock (18,333 underlying) - 66,667
8% Senior Convertible Debentures
Exercise: $0.30From: 2012-11-26Exp: 2015-11-26→ Common Stock (66,667 underlying) - 66,667
Series A Warrants (right to buy)
Exercise: $0.50From: 2012-11-26Exp: 2017-11-26→ Common Stock (66,667 underlying) - 137,500
Stock Option (right to buy)
Exercise: $0.30Exp: 2021-06-20→ Common Stock (137,500 underlying) - 80,000
Stock Option (right to buy)
Exercise: $0.30Exp: 2021-09-19→ Common Stock (80,000 underlying)
Footnotes (6)
- [F1]Shares issued in lieu of cash payment of liquidated damages in the amount of $387, pursuant to the terms of a Registration Rights Agreement dated November 26, 2012 among the Issuer and the investors identified therein, as amended on March 25, 2013.
- [F2]25% vested on 6/22/12 and thereafter in 24 equal monthy installments.
- [F3]On 6/22/2011, the Reporting Person was granted an option to purchase up to 112,500 shares of common stock of the Issuer. Up to 1/3 of the shares subject to the option may vest annually (or a pro rata portion thereof for a period of less than a full year) based on the achievement of certain performance milestones as determined by the Board of Directors (the 'Board') of the Issuer. On 1/17/2012, the Board determined that options for the prorated period ending 12/31/2011 would vest in the maximum potential amount of 20,034 shares. On 1/14/2013, the Board determined that options for the period ending 12/31/2012 would vest in the maximum potential amount of 37,500 shares.
- [F4]50% vested on 9/19/11 and thereafter in 24 equal monthly installments.
- [F5]1/3 vested on 1/14/13 and thereafter will vest in 24 equal monthy installments, commencing 1/31/13.
- [F6]On 1/14/2013, the Reporting Person was granted an option to purchase up to 55,000 shares of common stock of the Issuer. 1/3 of the shares subject to the option were immediately vested and up to 1/2 of the remaining shares subject to the option may vest annually, based on the achievement of certain performance milestones as determined by the Board.